1-1 of 1
David J. Price
Close
Sort by
Journal Articles

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

Clinical Trials & Observations
Justine E. Marum, David T. Yeung, Leanne Purins, John Reynolds, Wendy T. Parker, Doris Stangl, Paul P. S. Wang, David J. Price, Jonathan Tuke, Andreas W. Schreiber, Hamish S. Scott, Timothy P. Hughes, Susan Branford
Journal: Blood Advances
Blood Adv (2017) 1 (18): 1369–1381.
https://doi.org/10.1182/bloodadvances.2017006825
Published: 2017
Includes: Supplemental data